

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Multiple Technology Appraisal (MTA)

Desferrioxamine, deferiprone and deferasirox for the treatment of chronic iron overload in people with thalassaemia

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed:				
Provisional matrix of consultees and commentators sent for consultation				
Summary of comments, action taken, and justification of action:				
	<i>Proposal:</i>	<i>Proposal made by:</i>	<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>
1	Hospira is the manufacturer of desferrioxamine not Deferasirox	Dr Farrukh T Shah - British Society of Haematology	Corrected on final matrix	

2	The North of England Bone Marrow and Thalassaemia Association registered charity 702007 looks after and supports many thalassaemia families in the north of England. They should be an important part of the parent/carer organisation groups.	Dr Farrukh T Shah - British Society of Haematology	Not included	The North of England Bone Marrow and Thalassaemia Association is not a national organisation and therefore does not meet NICE's criteria for patient/carer groups.
3	Hospira is the manufacturer of desferrioxamine not Deferasirox	Professor John B Porter – The royal college of Pathologists	Corrected on final matrix	
4	The North of England Bone Marrow and Thalassaemia Association registered charity 702007 looks after and supports many thalassaemia families in the north of England. They should be an important part of the parent/carer organisation groups	Professor John B Porter – The royal college of Pathologists	Not included	The North of England Bone Marrow and Thalassaemia Association is not a national organisation and therefore does not meet NICE's criteria for patient/carer groups.
5	Hospira should be removed as one of the manufacturers for deferasirox because this drug is solely produced by Novartis. However both Novartis and Hospira should be listed as manufacturers of desferrioxamine – Novartis produces the branded version of desferrioxamine (Desferal) and Hospira the generic version.	Novartis Pharmaceuticals UK Ltd	Corrected on final matrix	

6	<p>The following consultees and commentators should be excluded from the list because they are not directly associated with the disease area covered under this scope:</p> <ul style="list-style-type: none"> • Sickle Cell Society • British Association for Services to the Elderly • British Geriatric Society • Royal Society of Medicine – Intellectual Disabilities Forum <p>Research Institute for the Care of Older People</p>	Novartis Pharmaceuticals UK Ltd	Not removed	<p>The Sickle Cell Society has been kept on the matrix because they appear to meet the inclusion criteria and appear to be relevant to thalassaemia.</p> <p>The “Royal Society of Medicine – Intellectual Disabilities Forum” should have been listed as the “Royal Society of Medicine”. This organisation is included on all NICE Technology Appraisal matrices.</p> <p>The following organisations meet the inclusion criteria for all NICE Technology Appraisals: British Association for Services to the Elderly British Geriatric Society The Research Institute for the Care of Older People is also included on all NICE matrices.</p>
7	<p>Only a detail – Hospira, which is a trade name I am not familiar with, is given in the draft scope as a formulation of desferrioxamine, whereas in the matrix it is given as a formulation of deferasirox.</p>	UK Forum on Haemoglobin Disorders	Corrected on final matrix	
8	<p>Add National Pharmacy Association.</p>	NICE Secretariat	Added	<p>The National Pharmacy Association meets the inclusion criteria and therefore this organisation has been added to the matrix as a professional organisation.</p>

8	<p>The draft scope states that the population under examination is limited to: "People with thalassaemia major who have developed chronic iron overload following blood transfusions."</p> <p>The matrix of consultees and commentators includes Sickle Cell Anaemia but excludes all other Haemoglobinopathies affected by chronic iron overload such as MDS, DBA, Fanconi's Anaemia. It should be clarified why they have been excluded or alternatively why only Sickle Cell Anaemia has been included in that list.</p>	United Kingdom Thalassaemia Society			
---	---	--	--	--	--